OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic

Collaborative, TO; Curtis, HJ; MacKenna, B; Walker, AJ; Croker, R; Mehrkar, A; Morton, C; Bacon, S; Hickman, G; Inglesby, P; Bates, C; Evans, D; Ward, T; Cockburn, J; Davy, S; Bhaskaran, K; Schultze, A; Rentsch, CT; Williamson, E; Hulme, W; Tomlinson, L; Mathur, R; Drysdale, H; Eggo, RM; Wong, AY; Goldacre, B

COVID-19 Collection

Journal article

OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic

Abstract:: BACKGROUND: Early in the COVID-19 pandemic, the National Health Service (NHS) recommended that appropriate patients anticoagulated with warfarin should be switched to direct-acting oral anticoagulants (DOACs), requiring less frequent blood testing. Subsequently, a national safety alert was issued regarding patients being inappropriately coprescribed two anticoagulants following a medication change and associated monitoring. OBJECTIVE: To describe which people were switched from warfarin to DOACs; identify potentially unsafe coprescribing of anticoagulants; and assess whether abnormal clotting results have become more frequent during the pandemic. METHODS: With the approval of NHS England, we conducted a cohort study using routine clinical data from 24 million NHS patients in England. RESULTS: 20 000 of 164 000 warfarin patients (12.2%) switched to DOACs between March and May 2020, most commonly to edoxaban and apixaban. Factors associated with switching included: older age, recent renal function test, higher number of recent INR tests recorded, atrial fibrillation diagnosis and care home residency. There was a sharp rise in coprescribing of warfarin and DOACs from typically 50-100 per month to 246 in April 2020, 0.06% of all people receiving a DOAC or warfarin. International normalised ratio (INR) testing fell by 14% to 506.8 patients tested per 1000 warfarin patients each month. We observed a very small increase in elevated INRs (n=470) during April compared with January (n=420). CONCLUSIONS: Increased switching of anticoagulants from warfarin to DOACs was observed at the outset of the COVID-19 pandemic in England following national guidance. There was a small but substantial number of people coprescribed warfarin and DOACs during this period. Despite a national safety alert on the issue, a widespread rise in elevated INR test results was not found. Primary care has responded rapidly to changes in patient care during the COVID-19 pandemic

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Collaborative, T. O., Curtis, H. J., MacKenna, B., Walker, A. J., Croker, R., Mehrkar, A., Morton, C., Bacon, S., Hickman, G., Inglesby, P., Bates, C., Evans, D., Ward, T., Cockburn, J., Davy, S., Bhaskaran, K., Schultze, A., Rentsch, C. T., Williamson, E., … Goldacre, B. (2021). OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic. Open Heart, 8(2), e001784–e001784.

MLA Style

Collaborative, TO, et al. “OpenSAFELY: Impact of National Guidance on Switching Anticoagulant Therapy during COVID-19 Pandemic.” Open Heart, vol. 8, no. 2, 2021, pp. e001784–e001784.

Chicago Style

Collaborative, TO, HJ Curtis, B MacKenna, et al. 2021. “OpenSAFELY: Impact of National Guidance on Switching Anticoagulant Therapy during COVID-19 Pandemic.” Open Heart 8 (2): e001784–e001784.
Print